TherapiAI, a leading force in AI-driven drug discovery, officially announced today (the 22nd) its strategic expansion into the Japanese market through a formal partnership with Chiral, an emerging Japanese AI scientific computing startup. This collaboration marks a significant milestone in TherapiAI’s expansion across the Asia-Pacific region.
Through this alliance, both parties will integrate their core technological strengths to co-develop an AI-powered Digital Twin platform spanning from “drug design to manufacturing optimization.” This initiative aims to reconstruct the cyber-physical decision-making framework for biopharmaceuticals—covering everything from R&D to production—and spearhead a new era of intelligent manufacturing driven by Digital Twin technology.
The biopharmaceutical industry currently faces a critical challenge: protein design and process development remain heavily dependent on expert experience. Meanwhile, manufacturing data is fragmented across isolated systems such as MES (Manufacturing Execution Systems), LIMS (Laboratory Information Management Systems), and QMS (Quality Management Systems), making integration and continuity extremely difficult. Furthermore, existing AI models often struggle to meet the stringent traceability requirements of GMP (Good Manufacturing Practice), resulting in a long-standing disconnect within the decision-making process.
The more fundamental issue is that the industry still lacks a Digital Twin system capable of synchronously mapping “molecular design, process development, and production decision-making.” As a result, an effective closed-loop optimization between R&D and manufacturing remains unattainable.
Establishing an End-to-End Digital Twin: From Molecule to Manufacturing
Headquartered in Fukuoka, Japan, Chiral specializes in AI-powered scientific computing. Its platform enables researchers to perform complex operations—such as protein structure prediction and molecular simulation—without requiring advanced programming skills, significantly lowering the barrier to entry for computational research. To date, Chiral has established strategic partnerships with prominent Japanese industry leaders, including IMSBIO, JBIC, and myPresto.
Through this collaboration, TherapiAI and Chiral will achieve deep integration via API, embedding Chiral’s molecular computing capabilities directly into the TherapiAI platform. This synergy will establish an “End-to-End Digital Twin” model that extends from the molecular level all the way to process development and production decision-making.
Three Key Application Scenarios: Building a Comprehensive Digital Twin Lifecycle
The integrated platform will encompass three critical stages of biopharmaceutical development:
Early-stage R&D
By leveraging 3D protein structure prediction and developability analysis, the platform accelerates the design of antibody and protein therapeutics, significantly reducing uncertainty during the early stages of R&D.
Process Development
AI predictive models provide high-precision forecasts for yield, purity, and bioactivity, significantly minimizing the frequency of time-consuming trial-and-error cycles.
Compliance & Quality
Automation of GMP documentation and workflows ensures a complete, traceable decision chain that fully complies with global regulatory requirements.
Through this integration, AI is no longer merely a supporting tool but the engine driving the entire drug lifecycle via a Digital Twin system. By ensuring continuous synchronization between virtual models and physical manufacturing processes, the platform creates a closed-loop optimization that evolves over time.
Leadership Perspective: Towards a Digital Twin Infrastructure
Michael Han, Founder and CEO of TherapiAI, stated:
“The competitiveness of the biopharmaceutical industry will hinge on whether AI can be truly integrated into every single stage of drug development. Our goal is not to implement AI as a series of isolated point solutions, but to build a Digital Twin Infrastructure for biopharmaceuticals. This enables companies to predict and optimize processes in a virtual environment, which then feeds back into physical production.”
Strategic Expansion in Japan: The Starting Point for Growth Across the Asia-Pacific
This collaboration also marks a pivotal strategic positioning for TherapiAI in the Japanese market. Both parties will jointly promote the adoption of AI-powered Digital Twin platforms among Japanese pharmaceutical and biotech companies, while establishing localized use cases through technical seminars and industry exchange events.
Looking ahead, there are plans to further expand into Singapore and other key biotech hubs across Asia, positioning Japan as the strategic anchor for TherapiAI’s growth in the Asia-Pacific region.
